Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-08-25

Clinical Trial Update: Clofarabine for Langerhans in Pedi [Phase 2]

View source ↗

Summary

A Phase 2 trial of Clofarabine for pediatric Langerhans cell histiocytosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Clolar (Clofarabine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Langerhans Cell Histiocytosis | Phase 2 | Status: WITHDRAWN